BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at Stifel’s 4th Annual CNS Day on Tuesday, March 29, 2022 at 11:30 a.m. ET.

See original here:
Praxis Precision Medicines to Present at Stifel’s 4th Annual CNS Day

REDWOOD CITY, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced changes to its management team, including the promotions of Jeet Mahal to the newly created position of Chief Operating Officer, and of Wendy Pang, M.D., Ph.D., to Senior Vice President of Research and Translational Medicine. Both promotions are effective as of March 21, 2022. Jasper also announced that a new position of Chief Medical Officer has been created, for which an active search is underway. Judith Shizuru, M.D. PhD, co-founder, and Scientific Advisory Board Chairwoman will lead clinical development activities on an interim basis and Kevin Heller, M.D., EVP of Research and Development, will be transitioning to a consultant role.

Read more here:
Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team

Four-way distribution partnership provides quality, consistent rasH2 supply to India and China, better serving global customers Four-way distribution partnership provides quality, consistent rasH2 supply to India and China, better serving global customers

Read more:
Taconic Biosciences Improves rasH2 Carcinogenicity Test System Access in Asia-Pacific Region

NANTES, France, March 21, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the United States Patent and Trademark Office (USPTO) has issued a first notice of allowance for a patent application covering OSE-279, an anti-PD1 monoclonal antibody, and its use in cancer treatment. This patent will strengthen the global intellectual property of OSE-279 and will provide the product protection until 2039.

Read the rest here:
OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer...

Philip Perera, M.D., to retire while continuing to participate as an advisor to Longboard Philip Perera, M.D., to retire while continuing to participate as an advisor to Longboard

More:
Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer

Announces decision to discontinue development of ORIC-101

Go here to read the rest:
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conferences in March:

Go here to see the original:
atai Life Sciences to Participate in Upcoming March Investor Conferences

MALVERN, Pa., March 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Excerpt from:
TELA Bio Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level. The batches in the table below are being recalled due to the potential clogging of the needle preventing the dispensing of epinephrine. US WorldMeds (USWM) exclusively markets and distributes SYMJEPI in the United States, under license from Adamis, the NDA holder. USWM will handle the entire recall process for Adamis, with Adamis oversight. SYMJEPI is manufactured and tested for Adamis by Catalent Belgium S.A.

See original here:
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect

FOSTER CITY, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH) and obesity, today reported top-line results from Part 1 of the Company’s Phase 1b AVIATION Trial of TERN-201, a vascular adhesion protein-1 (VAP-1) inhibitor in development for the treatment of patients with NASH.

See the rest here:
Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201

SOUTH SAN FRANCISCO, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2021.

Link:
DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden settings of care -

View post:
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of...

BILLERICA, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of distinguished and world-renowned leaders of the scientific community. The SAB will discuss with management potential new development opportunities that leverage the Company’s unique True Single Molecule Sequencing (tSMS®) technology across the “omics” fields, as well as advise management with their existing collaborative, scientific, & development partnerships. Each leader has previously utilized the tSMS platform and will leverage their expertise to provide valuable insight to our company.

Excerpt from:
SeqLL Announces Formation of Scientific Advisory Board

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Daniel Faga as interim president and chief executive officer (CEO), effective immediately. Mr. Faga currently serves on the company’s Board of Directors and will succeed Hamza Suria, who has stepped down from his role as president and CEO and as a board director.   Mr. Suria will continue to support the Company in an advisory capacity.

Read the original:
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

Orphazyme A/SCompany announcementNo. 12/2022www.orphazyme.comCompany Registration No. 32266355

See the original post:
Orphazyme A/S has filed for voluntary delisting of ADSs

FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced it has commenced an underwritten public offering.

Read the rest here:
Statera Biopharma Announces Proposed Underwritten Public Offering

MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development of its radiopharmaceutical production facility in Brussels South (Seneffe) in the Wallonia region of Belgium.

Read the original post:
Telix Radiopharmaceutical Production Facility Buildout Commences

MALVERN, Pa., March 21, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the appointment of Jessica Crespo, CPA, as Chief Accounting Officer and Senior Vice President, Finance. She assumed the role effective March 18, 2022.

View post:
Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance

GUANGZHOU, China, March 21, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2021.

Read more here:
Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results

-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses after 1 and 2 months of treatment, respectively, and these reductions increased up to 6 months-

Visit link:
ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3...